IACS-6274 Combination Shrinks Tumors in Ovarian Cancer Trial
An experimental drug combination shrank tumors in nine of 13 evaluable patients with advanced ovarian cancer, researchers reported in Barcelona. The early-stage trial involved 14 patients, and researchers have begun expanding it to assess the treatment in more people.

Researchers presented results in Barcelona showing that an IACS-6274 drug combination shrank tumors in nine of 13 evaluable patients with advanced ovarian cancer. The early-stage trial enrolled 14 patients with hard-to-treat disease.
The patients received IACS-6274 alongside bevacizumab, a targeted therapy, and the chemotherapy drug paclitaxel. The findings come from a small phase I trial designed to assess safety and early signs of activity.
The nine patients had confirmed partial responses, meaning their tumors shrank by at least 30% on scans. Three others had stable disease, while one left the trial after early disease progression.
Cancer remained under control in 11 of the 13 patients, or 85%, at 12 weeks. Treatment lasted beyond 37 months in a subset of patients.
Trial expands after early responses
Timothy Yap, professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, led the trial. The center invented IACS-6274 and conducted the study.
“We observed deep and very durable responses in patients with advanced, hard-to-treat ovarian cancer,” Yap said. He said patients also reported improvements in cancer-related symptoms.
Ten of the 13 patients with measurable tumors had a partial response or stable disease lasting at least four months, Yap said. That represented 77% of the group.
The 14 participants had an average age of 56 years, with ages ranging from 45 to 75. Tumors in 13 of them had not responded to platinum-based therapies.
Researchers have begun treating more patients. They plan to treat another 15, followed by a further 15 if the treatment continues to be effective.
Side effects and potential marker
Patients took 120 mg or 180 mg of IACS-6274 by mouth twice daily. They also received bevacizumab and paclitaxel intravenously in 21-day cycles.
Both IACS-6274 dose levels were well tolerated, researchers said. Common mild side effects included nausea, fatigue, hair loss, anemia, nosebleeds, low white blood cell counts, nail disorders and vision disturbances.
More serious side effects included low white blood cell counts, elevated blood pressure and anemia. They were treated successfully, and no side effects limited the treatment dose.
IACS-6274 blocks glutaminase-1, an enzyme involved in how cells use the nutrient glutamine. Yap said laboratory research found that blocking this pathway shrank resistant tumors, especially alongside bevacizumab and chemotherapy.
Researchers also examined tumor and blood samples for an enzyme called ASNS. Eight of the 14 patients had tumors lacking it, and six of those eight had partial responses on scans.
Yap said ASNS loss could be a potential marker of response to the combination, though researchers will study it further. Laboratory samples also suggested a possible route by which tumors might develop resistance.
Elena Garralda, chair of the symposium where the findings were presented, was not involved in the study. She called the results “encouraging” and said she looked forward to results from the expanded trial.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1Gold Silver Price November: Futures Rise Near Yearly Lows

- 2U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 32027 NFL Mock Draft Puts Ohio State’s Jeremiah Smith at No. 1

- 4Michael Clarke Says Sandpapergate Scars Drew Steve Smith to New York

- 5GTA 6 New Zealand Time Trick Is Not Guaranteed to Work

Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists















